Using proteomic data across multiple tumor types, TransPRECISE identified several key pathways linking patient tumors and cell lines (eg, receptor tyrosine kinase in kidney cancers, hormone signaling in ovarian cancers, and epithelial–mesenchymal transition pathway in melanoma and uterine cancers). This evidence concerns the gene NTRK1 and kidney cancer.